A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Matthew S. Davids, Haesook T. Kim, Caitlin L. Costello, Alex F. Herrera, Frederick L. Locke, Rodrigo O. Maegawa, Alexandra Savell, Michael Mazzeo, David E. Avigan, Yi-Bin Chen, Sarah Nikiforow, Vincent T. Ho, Corey S. Cutler, Edwin P. Alyea, Pavan Bachireddy, Catherine J. Wu, Howard Streicher, Edward D Ball, Asad Bashey, Robert J. Soiffer, Philippe Armand
Institutions: Dana-Farber Cancer Institute, University of California San Diego, City Of Hope National Medical Center, City of Hope, Moffitt Cancer Center, Eastern Maine Medical Center, Beth Israel Deaconess Medical Center, Harvard University, Massachusetts General Hospital, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2907592044